Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Immunoglobulin G × 90 days × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡